Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 68

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 68
---
 RISK FACTORS.

RISK FACTOR SUMMARY

Below is a summary of the principal factors that
make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion
of the risks summarized in this risk factor summary, and other risks that we face, can be found under the heading “Risk Factors”
in our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 filed with the SEC on June 26, 2025, or Annual Report, and
should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC
before making investment decisions regarding our securities.

    ·
    We have incurred significant losses and expect to continue to incur losses for the foreseeable future.

    ·
    We will require additional financing to sustain our operations, achieve our business objectives and satisfy our cash obligations, which may dilute the ownership of our existing stockholders.

    ·
    We have limited experience in identifying and working with large-scale contracts with medical device manufacturers; manufacture of our devices must comply with good manufacturing practices in the United States.

    ·
    Delays, interruptions or the cessation of production by our third-party suppliers of important materials or delays in qualifying new materials, has and may continue to prevent or delay our ability to manufacture our Hemopurifier.

    ·
    Our Hemopurifier technology may become obsolete.

    ·
    If we fail to comply with extensive regulations of U.S. and foreign regulatory agencies, the commercialization of our products could be delayed or prevented entirely.

    ·
    If we are unable to maintain compliance with the listing requirements of the Nasdaq Capital Market, our common stock may be delisted from the Nasdaq Capital Market, which could have a material adverse effect on our financial condition and could make it more difficult for you to sell your shares.

    ·
    
    As a public company with limited financial resources
    undertaking the launch of new medical technologies, we may have difficulty attracting and retaining executive management and directors.

    ·
    
    We plan to expand our operations, which may strain
    our resources; our inability to manage our growth could delay or derail implementation of our business objectives.

    ·
    
    Our success is dependent in part on our executive
    officers.

    ·
    Delays in successfully commencing or completing our planned clinical trials could jeopardize our ability to obtain regulatory approval and sustain our